What are the pros and cons of HBsAg loss as the endpoint for treatment? | Jordan Feld, MD, MPH скачать в хорошем качестве

What are the pros and cons of HBsAg loss as the endpoint for treatment? | Jordan Feld, MD, MPH

Topic: What are the pros and cons of HBsAg loss as the endpoint for treatment? Speaker: Jordan Feld, MD, MPH Presented at: International Workshop on HBV Cure 2018 Learn more about International Workshop on HBV Cure 2021 that will take place virtually on 26 September 2021 via hhttps://bit.ly/2SahmPj The field of HBV treatment is undergoing major changes and is on the verge of a paradigm shift. The many new treatment options that are becoming available are providing great hopes for decreasing the burden of the disease, simplifying treatment, and ultimately curing and eradicating HBV infection. Since 2014, the International Workshop on HBV Cure has been a scientific platform that acts as a catalyst to accelerate the progress for achieving a cure. Around the globe, more than 250 million people are chronically infected with hepatitis B (HBV). The purpose of the workshop is to inform the participants about the developments in the possibilities to find a cure for HBV. The meeting is highly interactive with input from experts out of the arena of basic, translational, and clinical HBV research. For the Enduring Materials of the 2018 edition visit https://bit.ly/33Vejxl For more medical education programs, as well as the latest scientific information, visit https://academicmedicaleducation.com/